Mayne Pharma Group Ltd
ASX:MYX

Watchlist Manager
Mayne Pharma Group Ltd Logo
Mayne Pharma Group Ltd
ASX:MYX
Watchlist
Price: 4.48 AUD 7.18% Market Closed
Market Cap: 381.1m AUD
Have any thoughts about
Mayne Pharma Group Ltd?
Write Note

Wall Street
Price Targets

MYX Price Targets Summary
Mayne Pharma Group Ltd

Wall Street analysts forecast MYX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MYX is 6.21 AUD with a low forecast of 5.99 AUD and a high forecast of 6.56 AUD.

Lowest
Price Target
5.99 AUD
34% Upside
Average
Price Target
6.21 AUD
39% Upside
Highest
Price Target
6.56 AUD
46% Upside
Mayne Pharma Group Ltd Competitors:
Price Targets
DPHARMA
Duopharma Biotech Bhd
20% Upside
UCB
Ucb SA
0% Upside
DERM
Journey Medical Corp
90% Upside
4502
Takeda Pharmaceutical Co Ltd
18% Upside
OGI
OrganiGram Holdings Inc
76% Upside
688321
Shenzhen Chipscreen Biosciences Co Ltd
59% Upside
PPLPHARMA
Piramal Pharma Ltd
14% Upside
300702
Zhejiang Tianyu Pharmaceutical Co Ltd
42% Upside

Revenue
Forecast

Revenue Estimate
Mayne Pharma Group Ltd

For the last 6 years the compound annual growth rate for Mayne Pharma Group Ltd's revenue is -5%. The projected CAGR for the next 3 years is 12%.

-5%
Past Growth
12%
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Mayne Pharma Group Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
19%
Average Beat

Net Income
Forecast

Net Income Estimate
Mayne Pharma Group Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is MYX's stock price target?
Price Target
6.21 AUD

According to Wall Street analysts, the average 1-year price target for MYX is 6.21 AUD with a low forecast of 5.99 AUD and a high forecast of 6.56 AUD.

What is Mayne Pharma Group Ltd's Revenue forecast?
Projected CAGR
12%

For the last 6 years the compound annual growth rate for Mayne Pharma Group Ltd's revenue is -5%. The projected CAGR for the next 3 years is 12%.

Back to Top